New heart drug LCZ696 could reduce heart failure deaths by 20%, scientists say

Researchers believe it could replace the widely-used enalapril in treatment

A new drug believed to cause a 20 per cent reduction in heart failure deaths could present a “major advance” in treatment.

The clinical trial of the compound, named LCZ696, was stopped early when the “remarkable” results produced a better survival rate than the current gold-standard treatment, enalapril.

The drug, which is on the World Health Organisation’s list of essential medicines, could be replaced according to scientists.

Professor John McMurray, a principal researcher from the University of Glasgow said: “We have what we believe is a much more effective replacement for one of the gold standard drugs for the treatment of heart failure.

“This is a major advance in the treatment of this terrible problem.”

Heart failure occurs when the organ has been damaged, by a heart attack for example, and cannot pump blood around the body effectively.

The body responds to the low flow of blood by producing hormones such as angiotensin II and noradrenaline that constrict blood vessels and make it harder for the failing heart to squeeze blood into them.

Success in keeping people alive after a heart attack has led to a rise in the number of people suffering from the long-term after-effects, which include debilitating heart failure Heart failure can be caused by a heart attack or long-term conditions Over time, the constant production of these hormones further damages the heart, blood vessels and kidneys.

Enalapril works by blocking or inhibiting the hormones and slowing down or reversing the condition’s decline.

Professor McMurray said LCZ696 has a similar impact but also offers additional benefits by boosting the production of beneficial hormones.

According to the research, published in the New England Journal of Medicine, the compound stimulates the kidneys to produce more urine and relax blood vessels, easing pressure on the heart.

Compared with enapril, Professor McMurray said LCZ696 made patients “live longer, stay out of hospital and feel better, fulfilling all our goals of treatment”.

“This is a remarkable finding and strongly supports using this new approach instead of an ACE inhibitor or ARB in the treatment of chronic heart failure,” he added.

The University of Glasgow said the two-year trial saw more than 8,400 patients with heart failure given either 200mg of LCZ696 twice daily or 10mg twice daily of enalapril in addition to recommended therapy in a bid to compare mortality and hospitalisation rates.

Early results indicated that 914 (22 per cent) of patients in the LCZ696 group died of cardiovascular causes, compared with 1,117 (26 per cent) in the enalapril group.

A further 711 (17 per cent) of patients receiving LCZ696 and 835 (20 per cent) of those receiving enalapril died of any cause.

This represented a 20 per cent reduction in death from cardiovascular causes and a 16 per cent reduction in death from any cause for those taking LCZ696.

The new compound also reduced hospitalisation for heart failure by a fifth, experts said.

It is not yet available to the public as the manufacturers, Novartis International, must gain the approval of the Medicines and Healthcare Products Regulatory Agency (MHRA) to sell the drug.

Additional reporting by PA

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
Life and Style
ebooksA superb mix of recipes serving up the freshest of local produce in a delicious range of styles
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Sales Executives - OTE £60,000

    £25000 - £60000 per annum: Recruitment Genius: Are you passionate about Custom...

    Recruitment Genius: Care Workers Required - The London Borough of Bromley

    £15000 per annum: Recruitment Genius: This homecare agency is based in Beckenh...

    Recruitment Genius: Sales Executives - OTE £50,000

    £25000 - £50000 per annum: Recruitment Genius: Are you passionate about Custom...

    Recruitment Genius: Sales Executives - OTE £50,000

    £25000 - £50000 per annum: Recruitment Genius: Are you passionate about Custom...

    Day In a Page

    Homeless Veterans appeal: 'You look for someone who's an inspiration and try to be like them'

    Homeless Veterans appeal

    In 2010, Sgt Gary Jamieson stepped on an IED in Afghanistan and lost his legs and an arm. He reveals what, and who, helped him to make a remarkable recovery
    Could cannabis oil reverse the effects of cancer?

    Could cannabis oil reverse effects of cancer?

    As a film following six patients receiving the controversial treatment is released, Kate Hilpern uncovers a very slippery issue
    The Interview movie review: You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here

    The Interview movie review

    You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here
    Serial mania has propelled podcasts into the cultural mainstream

    How podcasts became mainstream

    People have consumed gripping armchair investigation Serial with a relish typically reserved for box-set binges
    Jesus Christ has become an unlikely pin-up for hipster marketing companies

    Jesus Christ has become an unlikely pin-up

    Kevin Lee Light, aka "Jesus", is the newest client of creative agency Mother while rival agency Anomaly has launched Sexy Jesus, depicting the Messiah in a series of Athena-style poses
    Rosetta space mission voted most important scientific breakthrough of 2014

    A memorable year for science – if not for mice

    The most important scientific breakthroughs of 2014
    Christmas cocktails to make you merry: From eggnog to Brown Betty and Rum Bumpo

    Christmas cocktails to make you merry

    Mulled wine is an essential seasonal treat. But now drinkers are rediscovering other traditional festive tipples. Angela Clutton raises a glass to Christmas cocktails
    5 best activity trackers

    Fitness technology: 5 best activity trackers

    Up the ante in your regimen and change the habits of a lifetime with this wearable tech
    Paul Scholes column: It's a little-known fact, but I have played one of the seven dwarves

    Paul Scholes column

    It's a little-known fact, but I have played one of the seven dwarves
    Fifa's travelling circus once again steals limelight from real stars

    Fifa's travelling circus once again steals limelight from real stars

    Club World Cup kicked into the long grass by the continued farce surrounding Blatter, Garcia, Russia and Qatar
    Frank Warren column: 2014 – boxing is back and winning new fans

    Frank Warren: Boxing is back and winning new fans

    2014 proves it's now one of sport's biggest hitters again
    Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

    Jeb Bush vs Hillary Clinton

    Karen Tumulty explores the power dynamics of the two first families
    Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

    Stockholm is rivalling Silicon Valley

    The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
    Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

    Crucified Santa: Urban myth refuses to die

    The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
    Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

    The Boy in the Dress: On set with the stars

    Walliams' story about a boy who goes to school in a dress will be shown this Christmas